In 2023, industry is witnessing a renaissance in viral vector characterization. Spurred by widespread biopharma investment to engineer a new wave of novel capsids and faced with newly launched QbD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback